人福医药：重酒石酸去甲肾上腺素注射液获药品注册证书

Core Viewpoint - The approval of the drug by the National Medical Products Administration signifies the company's qualification to sell the product in the domestic market, enhancing its product line and potential revenue streams [1] Group 1: Company Developments - Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical, has received the drug registration certificate for Dexamethasone Injection from the National Medical Products Administration [1] - The drug is indicated for the control of blood pressure in certain acute hypotensive states, as well as for the auxiliary treatment of cardiac arrest and severe hypotension [1] - The projected national sales for the drug in 2024 are approximately 2.1 billion yuan [1]